BRPI0508160A - composições de vacina obtidas a partir de streptomyces - Google Patents

composições de vacina obtidas a partir de streptomyces

Info

Publication number
BRPI0508160A
BRPI0508160A BRPI0508160-2A BRPI0508160A BRPI0508160A BR PI0508160 A BRPI0508160 A BR PI0508160A BR PI0508160 A BRPI0508160 A BR PI0508160A BR PI0508160 A BRPI0508160 A BR PI0508160A
Authority
BR
Brazil
Prior art keywords
streptomyces
present
compositions obtained
vaccine compositions
vaccine
Prior art date
Application number
BRPI0508160-2A
Other languages
English (en)
Inventor
Maria Elena Sarmiento G Miguel
Armando Acosta Dominguez
Carlos Roman Vallin Plous
Nesty Olivares Arzuaga
Yamile Lopez Hernandez
Caridad Rodriguez Valdes
Maximo Martinez Benitez
Leonora Gonzalez Mesa
Juan Francisco Infante Bourzac
Astrid Ramos Mori
Original Assignee
Inst Finlay Ct De Investigacio
Ct De Quimica Farmaceutica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Finlay Ct De Investigacio, Ct De Quimica Farmaceutica filed Critical Inst Finlay Ct De Investigacio
Publication of BRPI0508160A publication Critical patent/BRPI0508160A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçõES DE VACINA OBTIDAS A PARTIR DE STREPTOMYCES. O presente invento se refere ao campo da imunologia e, mais especificamente, ao controle de doenças infecciosas causadas por micobactérias, que é baseado no uso de vacinas para a prevenção de ditas doenças. A vacina de acordo com o presente invento foi desenvolvida com o uso de cepas vivas de STREPTOMYCES, que podem ou não expressar antígenos de M. tuberculosais, e demonstraram sua capacidade protetora contra a ameaça de BCG e M. tuberculosais após serem administrados por rotas diferentes. O presente invento também se refere ao uso de cepas de STREPTOMYCES para a expressão de antígenos heterólogos de interesse de vacina.
BRPI0508160-2A 2004-03-18 2005-03-18 composições de vacina obtidas a partir de streptomyces BRPI0508160A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040051A CU23460A1 (es) 2004-03-18 2004-03-18 Composiciones vacunales obtenidas a partir de streptomyces
PCT/CU2005/000002 WO2005087259A1 (es) 2004-03-18 2005-03-18 Composiciones vacunales obtenidas a partir de streptomyces.

Publications (1)

Publication Number Publication Date
BRPI0508160A true BRPI0508160A (pt) 2007-08-07

Family

ID=40251560

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508160-2A BRPI0508160A (pt) 2004-03-18 2005-03-18 composições de vacina obtidas a partir de streptomyces

Country Status (15)

Country Link
US (1) US20070292452A1 (pt)
EP (1) EP1743651B1 (pt)
JP (1) JP4875606B2 (pt)
KR (1) KR20070026454A (pt)
CN (1) CN1960751A (pt)
AT (1) ATE419868T1 (pt)
AU (1) AU2005221262A1 (pt)
BR (1) BRPI0508160A (pt)
CA (1) CA2559633C (pt)
CU (1) CU23460A1 (pt)
DE (1) DE602005012252D1 (pt)
ES (1) ES2323080T3 (pt)
MX (1) MXPA06010616A (pt)
RU (1) RU2006136806A (pt)
WO (1) WO2005087259A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102100431B1 (ko) 2018-09-11 2020-04-13 한국해양과학기술원 스트렙토미세스로부터 유래된 새로운 화합물 및 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315579D0 (en) * 1983-06-07 1983-07-13 Biogen Nv Streptomyces expression systems
US6537558B2 (en) * 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
EP0962532A1 (en) * 1998-06-03 1999-12-08 Innogenetics N.V. Polypeptides and nucleic acids encoding the same for the diagnosis and prevention of tuberculosis disease.
DE60226175T2 (de) * 2001-11-14 2009-07-09 Novavax, Inc. Mycobakterieller impfstoff
KR100474111B1 (ko) * 2001-12-26 2005-03-10 한국생명공학연구원 스트렙토마이세스 속 ａｍｌｋ-335 균주 및 그 생산화합물의 용도

Also Published As

Publication number Publication date
MXPA06010616A (es) 2007-07-04
JP2007529432A (ja) 2007-10-25
RU2006136806A (ru) 2008-04-27
ES2323080T3 (es) 2009-07-06
CN1960751A (zh) 2007-05-09
US20070292452A1 (en) 2007-12-20
EP1743651B1 (en) 2009-01-07
CU23460A1 (es) 2009-12-01
WO2005087259A1 (es) 2005-09-22
EP1743651A1 (en) 2007-01-17
DE602005012252D1 (de) 2009-02-26
CA2559633A1 (en) 2005-09-22
CA2559633C (en) 2011-09-06
AU2005221262A1 (en) 2005-09-22
ATE419868T1 (de) 2009-01-15
JP4875606B2 (ja) 2012-02-15
KR20070026454A (ko) 2007-03-08

Similar Documents

Publication Publication Date Title
Agger et al. Tuberculosis subunit vaccine development: on the role of interferon-γ
Tkachuk et al. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
NO20090062L (no) Influensavaksine
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
TW200722101A (en) Novel composition
EA201001479A1 (ru) Вакцина
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
BRPI0816790A8 (pt) Composições farmacêuticas contendo toxóides a e b de clostridium difficile
WO2015103167A3 (en) Single vial vaccine formulations
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
BR112012016048A2 (pt) "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos".
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
MX2019012620A (es) Composiciones de vacunas.
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2021207281A3 (en) Vaccines, adjuvants, and methods of generating an immune response
BRPI0508160A (pt) composições de vacina obtidas a partir de streptomyces
PE20240800A1 (es) Composiciones de espirotetramato que comprenden adyuvantes
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
Montañés et al. New tuberculosis vaccines
WO2010080188A3 (en) Epitope targeted anthrax vaccine
Ullah et al. Differential Immunogenicity and Protective Efficacy Elicited by MTO‐and DMT‐Adjuvanted CMFO Subunit Vaccines against Mycobacterium tuberculosis Infection
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
MY141912A (en) Vaccine compositions obtained from streptomyces

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.